Weight Loss Drugs Land Medicare Coverage for Cardiovascular Events
CardiacWire
MARCH 24, 2024
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.
Let's personalize your content